Sign In
Buy QNCX
$23.39
+0.360 (+1.56%)
At Close: Jul 31, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential
11:08am, Monday, 12'th Jan 2026
Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery wi
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Rating of “Moderate Buy” from Brokerages
01:50am, Monday, 12'th Jan 2026
Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. One analyst has ra
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
01:58am, Thursday, 18'th Dec 2025
Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat Ratin
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
08:00am, Monday, 15'th Dec 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
04:05pm, Wednesday, 10'th Dec 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
Quince Therapeutics to Participate at Investor Events in December 2025
08:00am, Monday, 24'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
04:05pm, Wednesday, 12'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
04:05pm, Monday, 10'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript
05:12pm, Thursday, 02'nd Oct 2025
Quince Therapeutics, Inc. (NASDAQ:QNCX ) Analyst/Investor Day October 2, 2025 10:00 AM EDT Company Participants Dirk Thye - CEO, Chief Medical Officer & Director Giovanni Mambrini - Chief Technology O
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
04:05pm, Thursday, 25'th Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
Quince Therapeutics, Inc. - Special Call
01:13am, Wednesday, 24'th Sep 2025
Quince Therapeutics, Inc. - Special Call Company Participants Dirk Thye - CEO, Chief Medical Officer & Director Brendan Hannah - Chief Business Officer, COO, Chief Compliance Officer and Principal Fin
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
04:05pm, Thursday, 11'th Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
04:05pm, Tuesday, 02'nd Sep 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment
